2 ASX stocks to help turn $100,000 into $1 million

Let's see why these shares could be great compounders over the next decade and beyond.

Key points
  • CSL, a global biotech powerhouse, offers long-term stability and growth through its essential plasma therapies and vaccines, with a strong track record of steady earnings and reinvestment, making it a cornerstone for generational wealth creation.
  • Despite recent share price challenges due to external pressures, CSL's robust fundamentals and continuous R&D investment position it well for future compounding, appealing to those aiming for substantial long-term returns.
  • Life360 is experiencing rapid growth with its family safety platform, driven by increasing subscription rates and premium feature expansion, offering vast opportunities to monetize its significant active user base for transformative earnings potential.

Turning $100,000 into $1 million is the dream. But despite what you might read on social media, it doesn't happen overnight and it certainly doesn't happen without risk.

What can help everyday investors reach that milestone, however, is a combination of time, patience, and investments in high-quality ASX stocks that are capable of compounding earnings for many years.

The maths is surprisingly simple: at a 10% average annual return, money doubles roughly every seven years. That means a 10x return is absolutely possible over a 20 to 25-year horizon, but you need to own the right businesses.

With that in mind, listed below are two ASX stocks that stand out today as long-term compounders with the potential to help turn a $100,000 starting balance into something substantially bigger over time.

Happy man holding Australian dollar notes, representing dividends.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL is exactly the kind of stock that investors should own for generational wealth creation. It isn't flashy, speculative, or volatile. It is a global biotech powerhouse with irreplaceable assets, deep competitive moats, and decades of proven execution.

The company's plasma-derived therapies and vaccines serve millions of patients worldwide, and demand tends to grow steadily regardless of economic conditions. In addition, CSL continues to invest heavily in R&D to expand its pipeline, while also increasing its US manufacturing footprint to reduce supply-chain risk and support long-term margin recovery.

Although CSL's share price has struggled in 2025 due to tariff concerns, margin recovery delays, and uncertainty around the Seqirus spin-off, the fundamentals remain exceptionally strong.

More importantly, CSL has the kind of long-term growth engine that investors want when trying to multiply their wealth. Over the past two decades, the company has transformed many investors into millionaires through steady earnings growth and disciplined reinvestment. If it continues compounding at anything close to its historical rate, CSL could be a great holding in a balanced portfolio.

Life360 Inc. (ASX: 360)

Another ASX stock to buy could be Life360. The family safety and location-sharing platform has been delivering exceptional growth in recent years.

This has continued in 2025, with third quarter revenue rising 34% year on year to US$124.5 million. In addition, Annualised Monthly Revenue hit US$446.7 million, up 33%, and Paying Circles climbed to 2.7 million following a record quarter of additions.

Life360 is scaling rapidly across the US and internationally, underpinned by subscription growth, rising average revenue per user and expanding premium features.

With approximately 91.6 million monthly active users and just a fraction currently paying for premium features, Life360 has an enormous runway. If it successfully monetises even a modest portion of its global user base, the long-term earnings potential could be enormous.

Motley Fool contributor James Mickleboro has positions in CSL and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A couple sits on the bed in their hotel room wearing white robes, with both having seen bad news on their phones.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is delivering significant financial growth.

Read more »

Two work colleagues looking at a laptop and discussing something.
Growth Shares

If I could own just one ASX share for the next decade, these 5 would make my shortlist

Let's see which shares made the cut.

Read more »

Watering can pouring water on increasing piles of coins with green plants on them and a piggy bank and coins on the table.
Growth Shares

My $5k bullish growth play: 3 exciting ASX stocks I just bought for retirement

I’m excited by what these stocks could achieve in the future.

Read more »

Hourglass in a hand with white lines and dollar signs.
Growth Shares

2 top ASX shares to buy and hold for the next decade

I think these businesses have a very exciting future.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Growth Shares

Where I'd invest $10,000 in ASX growth shares

These shares have strong growth outlooks. Let's get to know them better.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Growth Shares

2 ASX growth shares I think could surprise investors by 2030

These two shares could have bucketloads of growth ahead of them.

Read more »

Happy businessman fist pumping while looking at a tablet.
Growth Shares

Why I think these shares could return more than the ASX 200 by 2030

Beating the market isn't easy, but I think these companies have qualities that could make it happen.

Read more »

Green arrow going up on a stock market chart, symbolising a rising share price.
Growth Shares

2 ASX shares tipped to grow up to 142% in the next 12 months

Analysts think these stocks are poised to deliver big returns.

Read more »